

	Tapering csDMARD first (n=94)	Tapering TNF-inhibitor first (n=95)
Oral glucocorticoids*, n (%)	5 (5)	6 (6)
Intra-articular glucocorticoids*, n (%)	20 (21)	23 (24)
Intramuscular glucocorticoids*, n (%)	7 (7)	11 (12)

*Numbers indicate number of patients who used glucocorticoids within the two years of follow-up.
csDMARD: conventional synthetic disease modifying anti-rheumatic drug, TNF: tumor necrosis factor.

Supplemental table S1 Glucocorticoid use within two years of follow-up